Nicolas Duployez, Molecular Biologist at Lille University Hospital, shared on X about a recent paper by Hartmut Döhner et al. titled “Genetic Risk Stratification and Outcomes Among Treatment-Naive Patients With AML Treated With Venetoclax and Azacitidine” published in Blood Journals.
Authors: Hartmut Döhner et al.
“ELN 2017/2022 prognostic classifiers did not adequately stratify OS outcomes for AML patients treated with VEN-based regimens.
A 4-gene prognostic model (TP53, FLT3-ITD, NRAS, and KRAS) stratified OS outcomes with VEN-AZA treatment in AML.”
Source: Nicolas Duployez/X